Results 71 to 80 of about 39,467 (264)

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

British Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan, Imran Omerdeen, Bethan Psaila   +2 more
wiley   +1 more source

Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.

PLoS ONE, 2020
The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis are hematopoietic stem cell disorders and share driver mutations that either directly activate the thrombopoietin receptor, MPL, or activate it ...
Jerry L Spivak, Akil Merchant, Donna M Williams, Ophelia Rogers, Wanke Zhao, Amy Duffield, Linda S Resar, Alison R Moliterno, Zhizhuang J Zhao   +8 more
doaj   +1 more source

Myeloproliferative neoplasms: a review of diagnostic criteria and clinical aspects [PDF]

, 2010
Chronic myeloproliferative disorders, currently called myeloproliferative neoplasms (MPN), according to the 4th edition of the World Health Organization (WHO) classification are clonal diseases of hematopoietic stem cells, in which there is increased ...
Chauffaille, Maria de Lourdes Lopes Ferrari
core   +1 more source

Mapping VEXAS‐associated and rare UBA1 variants in the United Kingdom: Insights from patient cohorts and the general population

British Journal of Haematology, EarlyView.
VEXAS syndrome is a late‐onset inflammatory disorder with rheumatological and haematological features. Epidemiological studies of VEXAS syndrome so far have been limited. Analysis of various UK cohorts estimates the incidence of VEXAS to be 1.51/100 000, or 171 new cases in the population of men over the age of 50 who are being investigated for myeloid
Ana Martinez Rodriguez, Leon Chang, Dorota Rowczenio, Alexandra Smith, Ebun Omoyinmi, James A. Poulter, Andrew McGregor, Sebastian Francis, Roochi Trikha, Adam Al‐Hakim, Kar Lok Kong, David G. Kent, Helen Lachmann, Austin Kulasekararaj, Catherine Cargo, Sinisa Savic   +15 more
wiley   +1 more source

Concomitant BCR-ABL1 positive chronic myelogenous leukemia emerging in a patient with MPL W515L associated primary myelofibrosis

Human Pathology: Case Reports, 2016
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by proliferation of one or more cell lineages in the bone marrow.
Juan C. Gomez-Gelvez, MD, Elena Ivan, MD, Bryan L. Betz, PhD, Megan S. Lim, MD, PhD   +3 more
doaj   +1 more source

Contraception in Myeloproliferative Neoplasms: A Pharmacological Review. [PDF]

Eur J Haematol
ABSTRACT Myeloproliferative neoplasms (MPNs) are chronic hematologic disorders characterized by clonal proliferation of myeloid lineage cells, commonly driven by JAK2 mutations, and associated with significant thrombotic and hemorrhagic complications.
Alshurafa A, Benkhadra M, Babiker AM, Mohammed WM, Yassin MA.   +4 more
europepmc   +2 more sources

Familial Myeloproliferative Disorders [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018
Review on Familial Myeloproliferative Disorders, with data on clinics, and the genes involved.
Bellanné-Chantelot, Christine, Plo, Isabelle   +1 more
openaire   +3 more sources

Differential NOD/SCID mouse engraftment of peripheral blood CD34 + cells and JAK2V617F clones from patients with myeloproliferative neoplasms [PDF]

, 2010
We evaluated the NOD/SCID engraftment of CD34 + cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34 + cells were transplanted intra-femorally.
Cheung, AMS, Fung, TK, Kwong, YL, Leung, AYH, Liang, R   +4 more
core   +1 more source

Primary myelofibrosis with increased haemoglobin concentration at presentation

British Journal of Haematology, EarlyView.
Subjects with primary myelofibrosis and elevated haemoglobin levels at diagnosis tend to have longer survival rates (OS) and blast transformation‐free survival (BTFS) than those with normal or reduced haemoglobin levels. Summary One hundred of 963 consecutive registrants with primary myelofibrosis (PMF) in the Pavia‐CSM database had haemoglobin ...
Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Carlotta Abbà, Adriana Carolei, Margherita Massa, Annalisa De Silvestri, Robert Peter Gale, Vittorio Rosti   +8 more
wiley   +1 more source

Portal vein thrombosis after laparoscopic splenectomy: an ongoing clinical challenge. [PDF]

, 2005
ObjectivesPortal vein thrombosis (PVT) following open splenectomy is a potentially lethal complication with an incidence of up to 6%. The objective of this report is to describe our management of a recent laparoscopic case, discuss current therapies, and
Kee, Stephen T, Krummel, Thomas M, Mallory, Baird, Miniati, Douglas N, Padidar, Arash M   +4 more
core   +2 more sources